Tesaro Inc. (NASDAQ:TSRO) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $94.48 and last traded at $93.62, with a volume of 853,419 shares changing hands. The stock had previously closed at $93.38.

TSRO has been the subject of several research reports. Mizuho reiterated an “outperform” rating and set a $67.00 price target on shares of Tesaro in a report on Thursday, June 30th. FBR & Co reiterated a “buy” rating on shares of Tesaro in a report on Thursday, June 30th. Wells Fargo & Co. reiterated an “outperform” rating on shares of Tesaro in a report on Thursday, June 30th. Wedbush reiterated an “outperform” rating and set a $72.00 price target on shares of Tesaro in a report on Wednesday, April 6th. Finally, Zacks Investment Research upgraded Tesaro from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $76.50.

The company has a 50-day moving average of $71.05 and a 200 day moving average of $49.11. The firm’s market cap is $4.27 billion.

Tesaro (NASDAQ:TSRO) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by $0.53. The business earned $0.31 million during the quarter, compared to the consensus estimate of $2.48 million. During the same period in the prior year, the business earned ($1.30) EPS. On average, analysts anticipate that Tesaro Inc. will post ($7.16) earnings per share for the current year.

In other news, VP Edward C. English sold 7,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $40.75, for a total transaction of $285,250.00. Following the completion of the transaction, the vice president now directly owns 3,500 shares of the company’s stock, valued at $142,625. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jeffrey H. Hanke sold 12,500 shares of the company’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $74.35, for a total value of $929,375.00. Following the transaction, the vice president now directly owns 12,500 shares of the company’s stock, valued at $929,375. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors boosted its position in Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 330 shares in the last quarter. California State Teachers Retirement System boosted its position in Tesaro by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,152 shares of the biopharmaceutical company’s stock valued at $2,258,000 after buying an additional 752 shares in the last quarter. Rhumbline Advisers boosted its position in Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares in the last quarter. Mutual of America Capital Management LLC boosted its position in Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock valued at $2,068,000 after buying an additional 19,320 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock valued at $1,275,000 after buying an additional 24,119 shares in the last quarter.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.